Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness; it encompasses multiple forms of chronic arthritis in children. The burden of the disease can be exacerbated by progressive deterioration from the arthritis, which affects some patients for life. Current treatment of JIA comprises corticosteroids, nonsteroidal anti-inflammatory drugs, and disease-modifying antirheumatic drugs (DMARDs)—including targeted biologics—which are prescribed to control pain, improve function, and reduce inflammation. Driven by the incentives of the Pediatric Research Equity Act and Best Pharmaceuticals for Children Act, the clinical pipeline in JIA is active, comprising oral and biologic DMARDs approved to treat adult rheumatological disorders—primarily rheumatoid arthritis. According to interviewed JIA experts, there is room for drugs with improved efficacy and/or a milder side-effect profile, to facilitate chronic therapy in the management of JIA.

Questions Answered

  • How large are the U.S. and EU5JIA patient populations, and how will their size change through 2026? How large are the key International League of Associations for Rheumatology (ILAR) subpopulations? What percentage of the JIA population receives prescription drug treatment?
  • How are JIA patients diagnosed and managed? What are the key current therapies prescribed for JIA, and what drives their use?
  • What are the key unmet needs in JIA, and to what extent will they be fulfilled by the therapies in the JIA pipeline?
  • What clinical and commercial impact will emerging drugs have on the JIA therapy market through 2026?

Scope:

  • Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
  • Primary research: Six country-specific interviews with pediatric rheumatologists.
  • Epidemiology: Diagnosed incident cases of JIA, diagnosed and drug-treated prevalent cases of JIA, diagnosed prevalent cases of JIA by ILAR subtype and by age-group.
  • Market forecast: Drug-level sales and patient share of key JIA therapies in 2026.
  • Emerging therapies: Phase III: 3 drugs. Phase II: 1 drugs. Coverage of select Phase I/II and I products.
  • Key companies: AbbVie, Amgen, Bristol-Myers Squibb, Genentech, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sobi, UCB.
  • Key drugs: Humira, etanercept, Enbrel, infliximab, Remicade, tocilizumab, Actemra, RoActemra, anakinra, Kineret, canakinumab, Ilaris, abatacept, Orencia, certolizumab pegol, Cimzia, golimumab, Simponi, sarilumab, Kevzara, tofacitinib, Xeljanz, secukinumab, Cosentyx, sirukumab.

Table of contents

  • Juvenile Idiopathic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Key Findings
        • Regional Sales of Key Therapies to Treat Juvenile Idiopathic Arthritis, 2026
        • Juvenile Idiopathic Arthritis SWOT Analysis
        • Actionable Recommendations in Juvenile Idiopathic Arthritis, According to Pediatric Rheumatologists
    • Commercial Outlook
      • Key Findings
        • Expert Insight
      • Drivers and Constraints
        • What Factors Are Driving Sales in Juvenile Idiopathic Arthritis?
        • What Factors Are Constraining Sales in Juvenile Idiopathic Arthritis?
        • Class Patient Share Among Biologic-Treated Juvenile Idiopathic Arthritis Patients in 2026
      • Drug-Class-Specific Trends
        • TNF-Alpha Inhibitors
        • Janus Kinase Inhibitors
        • Interleukin-6 Inhibitors
        • Interleukin-1 Inhibitors
        • T-Cell Inhibitors
        • Interleukin-17 Inhibitors
    • Forecast
      • Sales of Key Therapies for Juvenile Idiopathic Arthritis in 2026
    • Etiology and Pathophysiology
      • Key Findings
        • Disease Overview
        • Expert Insight
      • Juvenile Idiopathic Arthritis Classification
        • Risk Factors
          • Pathophysiology of Juvenile Idiopathic Arthritis
            • Joint Inflammation and Destruction in Juvenile Idiopathic Arthritis
          • Key Pathways and Drug Targets
            • Targets of Biologic Therapies Used to Treat Juvenile Idiopathic Arthritis
        • Epidemiology Overview
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis
              • Number of Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis in the Major Pharmaceutical Markets, 2016-2026
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Incident Cases of Juvenile Idiopathic Arthritis
              • Number of Diagnosed Incident Cases of Juvenile Idiopathic Arthritis in the Major Pharmaceutical Markets, 2016-2026
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis by Subpopulation
              • Number of Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis in the Major Pharmaceutical Markets by Subpopulation, 2016-2026
              • Sources Used for Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis by Age Distribution
              • Number of Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis in the Major Pharmaceutical Markets by Age Distribution, 2016-2026
              • Sources Used for Drug-Treated Prevalence of Juvenile Idiopathic Arthritis
              • Drug-Treated Prevalent Cases of Juvenile Idiopathic Arthritis, 2016 and 2026
          • Current Treatment Overview
            • Key Findings
              • Expert Insight
            • Diagnosis
              • Diagnostic Tools for Juvenile Idiopathic Arthritis
              • Expert Insight on Diagnosis
              • Expert Insight on Treatment Providers and Referral Patterns
            • Treatment Goals
              • Key End Points Used in Clinical Trials for Juvenile Idiopathic Arthritis
              • Physician Insight on Clinical End Points
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Therapies Used for Juvenile Idiopathic Arthritis
              • Current Treatments Used for Juvenile Idiopathic Arthritis
              • Market Events Impacting the Use of Key Current Therapies in JIA
              • Advantages and Disadvantages of NSAIDs in JIA
              • Expert Insight
              • Select Conventional DMARDs in the Treatment of JIA
              • Advantages and Disadvantages of Conventional DMARDs in JIA
              • Expert Insight
              • Biologic DMARDs Used for the Treatment of JIA
              • Clinical Trial Outcomes for Humira
              • Clinical Analysis of Humira for the Treatment of JIA
              • Ongoing Clinical Development
              • Advantages and Disadvantages of Humira
              • Expert Insight: Humira
              • Clinical Trial Outcomes for Etanercept
              • Clinical Analysis of Etanercept for the Treatment of JIA
              • Advantages and Disadvantages of Etanercept
              • Expert Insight: Etanercept
              • Clinical Analysis of Simponi for the Treatment of JIA
              • Key Ongoing Clinical Trials of Simponi in the Treatment of JIA
              • Advantages and Disadvantages of Simponi
              • Clinical Trial Outcomes for Infliximab
              • Advantages and Disadvantages of Infliximab
              • Expert Insight: Infliximab
              • Clinical Trial Outcomes for Actemra/RoActemra
              • Clinical Analysis of Actemra/RoActemra for the Treatment of JIA
              • Ongoing Clinical Development
              • Advantages and Disadvantages of Actemra/RoActemra
              • Expert Insight: Actemra/RoActemra
              • Clinical Trial Outcomes for Kineret
              • Advantages and Disadvantages of Kineret
              • Expert Insight: Kineret
              • Clinical Analysis of Ilaris for the Treatment of JIA
              • Ongoing Clinical Development
              • Advantages and Disadvantages of Ilaris
              • Expert Insight: Ilaris
              • Clinical Trial Outcomes for Orencia
              • Clinical Analysis of Orencia for the Treatment of JIA
              • Ongoing Clinical Development
              • Advantages and Disadvantages of Orencia
              • Expert Insight: Orencia
            • Medical Practice
              • Key Treatment Guidelines
              • Expert Insight on Guidelines for JIA
              • Factors Influencing Drug Selection in JIA
              • Generalized Treatment Decision Tree for Juvenile Idiopathic Arthritis
          • Unmet Need Overview
            • Key Findings
              • Expert Insight
            • Attainment of Unmet Needs
              • Current Attainment of Unmet Needs in Juvenile Idiopathic Arthritis
              • Future Attainment of Unmet Needs in Juvenile Idiopathic Arthritis
              • Top Unmet Needs in Juvenile Idiopathic Arthritis: Current and Future Attainment
              • Expert Insight: Unmet Needs in Juvenile Idiopathic Arthritis
          • Emerging Therapies Overview
            • Key Findings
              • Expert Insight
              • Pipeline Trends for Juvenile Idiopathic Arthritis
            • Key Emerging Therapies
              • Notable Developments Among Key Emerging Therapies for Juvenile Idiopathic Arthritis
              • Key Emerging Therapies in Development for Juvenile Idiopathic Arthritis
              • Estimated Approval Dates of Key Emerging Therapies for the Treatment of Juvenile Idiopathic Arthritis
              • Cimzia Profile
              • Cimzia Clinical Development
              • Key Ongoing Clinical Trials of Cimzia
              • Expert Insight on Use of Cimzia in the Treatment of Juvenile Idiopathic Arthritis
              • Expert Insight: Cimzia
              • Expectations for Market Authorization and Sales Opportunity for Cimzia in Juvenile Idiopathic Arthritis
              • Key Ongoing Clinical Trials of Kevzara in the Treatment of JIA
              • Expert Insight on Use of Kevzara in the Treatment of Juvenile Idiopathic Arthritis
              • Expert Insight: Kevzara
              • Expectations for Market Authorization and Sales Opportunity of Kevzara in Juvenile Idiopathic Arthritis
              • Xeljanz Profile
              • Xeljanz Clinical Development
              • Key Ongoing Clinical Trials of Xeljanz in the Treatment of Juvenile Idiopathic Arthritis
              • Expert Insight on Use of Xeljanz in the Treatment of Juvenile Idiopathic Arthritis
              • Expert Insight: Xeljanz
              • Expectations for Market Authorization and Sales Opportunity of Xeljanz in Juvenile Idiopathic Arthritis
              • Cosentyx Clinical Development
              • Key Ongoing Clinical Trials of Cosentyx in the Treatment of Juvenile Idiopathic Arthritis
              • Expert Insight on Use of Cosentyx in the Treatment of Juvenile Idiopathic Arthritis
              • Expert Insight: Cosentyx
              • Expectations for Market Authorization and Sales Opportunity of Cosentyx in Juvenile Idiopathic Arthritis
              • Notable Therapies in Development for RA
            • Early-Phase Pipeline Analysis
              • Notable Developments in the Early-Phase Pipeline for Juvenile Idiopathic Arthritis
            • Key Discontinuations and Failures in Juvenile Idiopathic Arthritis
              • Patient Registries
                • Patient Registries for JIA
                • Prominent JIA Patient Organizations
              • Orphan Drug Designation
                • Orphan Drug Designations in JIA
              • Orphan Drug Designation
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                • Methodology
                  • Bottom-Up Forecasting Overview
                    • Patient Populations
                    • Drug-Specific Assumptions
                  • Bottom-Up Forecast Assumptions
                    • General Sources of Data
                    • Drug Treatment Rate Assumptions in Juvenile Idiopathic Arthritis
                    • Patient-Share Assumptions in Juvenile Idiopathic Arthritis
                    • General Statements About Pricing
                    • Sources for Drug Prices
                    • 2016 Exchange Rates
                    • Price per Treated Day: 2026
                    • Dosing, Days of Therapy, and Compliance
                    • Biosimilar Erosion
                    • Biosimilar Erosion Assumptions
                    • Out-Year Forecasting
                    • Emerging Therapy Prices
                  • Primary Market Research
                    • Experts Interviewed
                • Appendix
                  • Key Abbreviations Related to Juvenile Idiopathic Arthritis
                  • Brands, Marketers, and Generic Availability of Key Therapies for Juvenile Idiopathic Arthritis, by Market
                  • Juvenile Idiopathic Arthritis Bibliography

              Author(s): Akash Saini, Ph.D.; Abey John, MPH

              Akash is a Principal Analyst in the China In-Depth team at Decision Resources Group. Since 2016, he has specialized in a range of indications including rare disease indications such as DMD, ALS, ITP, IPF, JIA, and retinitis pigmentosa. He has authored Disease Landscape & Forecast reports, Access & Reimbursement reports, and Treatment Algorithm reports based on primary market research and real-world evidence. Prior to joining DRG, Akash was a post-doctoral fellow at the University of Massachusetts Medical School. He has a Ph.D. from the International Centre for Genetic Engineering and Biotechnology, New Delhi.

              Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

              Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


              Related Reports

              Juvenile Idiopathic Arthritis - Epidemiology - Mature Markets

              DRG Epidemiology's coverage of juvenile idiopathic arthritis (JIA) comprises epidemiological estimates of key patient populations across the major...

              View Details